Head-to-head evidence
Olanzapine (Zyprexa) vs Risperidone (Risperdal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00712686 · Phase 3 · completed
The study was a large randomized, double-blind, active-controlled comparison of aripiprazole and olanzapine, with clinical outcomes including PANSS symptom scores. Because the registry does not report whether either primary endpoint was met, the treatment comparison cannot be judged as positive, negative, or mixed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Risperidone (Risperdal)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
The study randomized 458 participants to double-blind risperidone or placebo, with change in the clinical PANSS score as the primary endpoint. Because the registry does not report whether this endpoint was met, the trial provides a well-controlled design but no assessable result.
Next expected readout: December 2026 · NCT06482554 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa)'s landscape · Risperidone (Risperdal)'s landscape